SCHEMBL623132

SCHEMBL623132

CC(C)Oc1cc(N2CCN(C(=O)c3csc(-c4ccccc4)n3)CC2)ncn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.42
LRRK2 Q5S007 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TLR7 Q9NYK1 1/20 0.39
CCKAR P32238 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
PIN1 Q13526 2/20 0.38
SCN9A Q15858 1/20 0.38
HTR2C P28335 2/20 0.38
ACACB O00763 1/20 0.38
ACKR3 P25106 1/20 0.38
SCD O00767 1/20 0.38
SCD5 Q86SK9 1/20 0.38
P2RY12 Q9H244 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL622745 0.90 IRAK4 (0.47) TLR7HDAC6
SCHEMBL623163 0.89 ALDH1A1 (0.41) LRRK2KDM4EALDH1A1LMNAGAA
SCHEMBL623783 0.89 PTGDR2 (0.43) PTGDR2TLR7PIN1HTR2CACKR3
SCHEMBL624123 0.84 PTGDR2 (0.43) PTGDR2ALDH1A1HTTTLR7CCKAR
SCHEMBL623175 0.80 IRAK4 (0.44) TLR7HDAC6
SCHEMBL623490 0.80 ALDH1A1 (0.39) KDM4EALDH1A1HPGDHTTHTR2C
SCHEMBL624219 0.78 ALDH1A1 (0.42) KDM4EALDH1A1HPGDHTTHTR2C
SCHEMBL624207 0.78 KMT2A (0.47) LRRK2ALDH1A1LMNAGAAHDAC1
SCHEMBL622326 0.77 TACR3 (0.49) LRRK2KDM4EALDH1A1LMNAGAA
SCHEMBL624238 0.74 L3MBTL1 (0.44) KDM4EALDH1A1LMNAGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G PTGDR2 918/4885LRRK2 2278/4885KDM4E 1537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.